Run by a veteran of drug R&D for Alzheimer’s disease, Alzheon is betting that a smart trial design and a little chemistry work could turn a failed drug for the memory-robbing disorder into a success. Alzheon president and CEO Martin Tolar says the company will spend the next six months “fine tun[ing]” things, like developing a once-a-day pill of its drug, now called ALZ-801. Then it’s on to a Phase 2/3 trial, which Alzheon aims to start by the end of the year. The $10 million will get Alzheon to that point—Tolar says Alzheon plans to raise more cash later this year to push through the coming trial.